Search research articles
Contact Us
Filters
Showing results (1-10 of 88) with videos related to
Page
of 9
Sort By:
Metabolism: Clinical and Experimental
|
January 20, 2019
Fibroblast growth factor 21: A role in cardiometabolic disorders and cardiovascular risk prediction?
Niki Katsiki, Christos Mantzoros
American Journal of Infectious Diseases
|
December 22, 2006
Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications
Sotirios Tsiodras, Christos Mantzoros
Metabolism: Clinical and Experimental
|
August 11, 2020
Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)/DASH (dysmetabolism associated steatohepatitis)
Niki Katsiki, Christos Mantzoros
Nestle Nutrition Institute Workshop Series
|
March 19, 2013
Early growth and development of later life metabolic disorders
Joo-Pin Foo, Christos Mantzoros
The Journal of Endocrinology
|
July 25, 2014
20 years of leptin: role of leptin in human reproductive disorders
Sharon H Chou, Christos Mantzoros
Metabolism: Clinical and Experimental
|
November 7, 2017
Bone metabolism in anorexia nervosa and hypothalamic amenorrhea
Sharon H Chou, Christos Mantzoros
Expert Review of Clinical Pharmacology
|
August 4, 2022
Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes
Manfredi Rizzo, Francesco Cosentino, Christos Mantzoros
Metabolism: Clinical and Experimental
|
March 31, 2020
New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective
Niki Katsiki, Ele Ferrannini, Christos Mantzoros
Metabolism: Clinical and Experimental
|
July 14, 2019
Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
Niki Katsiki, Nikolaos Perakakis, Christos Mantzoros
Current Vascular Pharmacology
|
April 29, 2020
Abnormal Peri-organ-Intra-organ Fat (APIFat) and Rheumatoid Arthritis: An Under-investigated Link for Increased Cardiovascular Risk?
Niki Katsiki, Dimitri P Mikhailidis, Christos Mantzoros
Page
of 9
Search research articles
Search
Showing results (1-10 of 88) with videos related to
Sort By:
Page
of 9
Metabolism: Clinical and Experimental
|
January 20, 2019
Fibroblast growth factor 21: A role in cardiometabolic disorders and cardiovascular risk prediction?
Niki Katsiki, Christos Mantzoros
American Journal of Infectious Diseases
|
December 22, 2006
Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications
Sotirios Tsiodras, Christos Mantzoros
Metabolism: Clinical and Experimental
|
August 11, 2020
Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)/DASH (dysmetabolism associated steatohepatitis)
Niki Katsiki, Christos Mantzoros
Nestle Nutrition Institute Workshop Series
|
March 19, 2013
Early growth and development of later life metabolic disorders
Joo-Pin Foo, Christos Mantzoros
The Journal of Endocrinology
|
July 25, 2014
20 years of leptin: role of leptin in human reproductive disorders
Sharon H Chou, Christos Mantzoros
Metabolism: Clinical and Experimental
|
November 7, 2017
Bone metabolism in anorexia nervosa and hypothalamic amenorrhea
Sharon H Chou, Christos Mantzoros
Expert Review of Clinical Pharmacology
|
August 4, 2022
Biosimilar and generic formulations of novel antidiabetic drugs: the role of liraglutide in clinical pharmacology of type 2 diabetes
Manfredi Rizzo, Francesco Cosentino, Christos Mantzoros
Metabolism: Clinical and Experimental
|
March 31, 2020
New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective
Niki Katsiki, Ele Ferrannini, Christos Mantzoros
Metabolism: Clinical and Experimental
|
July 14, 2019
Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
Niki Katsiki, Nikolaos Perakakis, Christos Mantzoros
Current Vascular Pharmacology
|
April 29, 2020
Abnormal Peri-organ-Intra-organ Fat (APIFat) and Rheumatoid Arthritis: An Under-investigated Link for Increased Cardiovascular Risk?
Niki Katsiki, Dimitri P Mikhailidis, Christos Mantzoros
Page
of 9